Health Care [ 8/12 ] | Biotechnology [ 36/76 ]
NASDAQ | Common Stock
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.
The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD.
Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 28, 24 | 0.00 | -0.50 Increased by +100.00% |
| Nov 13, 23 | -0.51 | -0.41 Decreased by -24.39% |
| Jul 17, 23 | -3.78 | -1.70 Decreased by -122.35% |
| May 31, 23 | -2.38 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -20.84 M Decreased by N/A% | Decreased by N/A% - |
| Jun 30, 23 | 0.00 Decreased by N/A% | -18.89 M Decreased by N/A% | Decreased by N/A% - |
| Mar 31, 23 | 0.00 - | -12.53 M - | Decreased by N/A% - |
| Sep 30, 22 | N/A - | -19.66 M - | - - |
| Jun 30, 22 | N/A - | N/A - | - - |
| Mar 31, 22 | N/A - | N/A - | - - |